알림

Champions Oncology Inc. (CSBR)

NasdaqCM: CSBR · 실시간 가격 · USD

5.09

+0.06 (1.19%)

종가 기준: Aug 18, 2026, 3:59 PM

5.08

-0.20%

애프터마켓: 4:10 PM

1.19% (1D)

매수호가	3.78
시가총액	70.72M
매출 (ttm)	59.42M
순이익 (ttm)	-1.18M
베타	0.41
EPS (ttm)	-0.08
P/E (ttm)	n/a
선행 P/E	50.9
P/B (ttm)	17.92
P/S (ttm)	1.19
Earnings Date	Dec 14, 2020

매도호가	6.74
거래량	10,864
평균 거래량 (20일)	9,250
시가	5.24
전일 종가	5.03
일중 범위	5.04 - 5.33
52주 범위	4.88 - 8.74
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CSBR 소개

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug deve...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 2, 2007

직원 수 214

상장 거래소 NasdaqCM

티커 CSBR

웹사이트 https://www.championsoncology.com

전체 기업 정보

재무 실적

2026년 Champions Oncology의 매출은 59.42M로, 전년 56.94M 대비 4.36% 증가했습니다. 순이익은 -1.18M로, -124.99% 감소했습니다.

재무제표

어닝 서프라이즈

Champions Oncology가 Dec 15, 2025에 분기 실적을 발표했습니다:

매출 $13.84M 예상치 하회 $0, 및 11.98% 전년 대비 성장.

EPS 0.06 예상치 하회 , 및 20.00% 전년 대비 성장.

다음 실적 발표

Champions Oncology Inc.의 실적 발표 예정일은 Dec 14, 2020, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · Zacks

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.

2주 전 · GuruFocus.com

Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ...

Champions Oncology Inc (CSBR) achieved record annual revenue of $59.4 million and its fourth consecutive quarter of positive adjusted EBITDA, despite a significant drop in data-license revenue.

3주 전 · MarketBeat

Champions Oncology Q4 Earnings Call Highlights

Champions Oncology (NASDAQ:CSBR) reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or...

3주 전 · Zacks

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.

3주 전 · Zacks

2 Microcaps With Gross Margin Catalysts

CSBR and CEPL have levers in place for Gross Margin improvement.

2 페이지 중 1

Champions Oncology Inc. (CSBR)